Kuick Research published an analysis claiming that the U.S. transdermal patch drug market is revolving on account of two powerful “mega-trends.” Those trends — acceleration in the U.S. pharmaceutical market growth and the restructuring of the healthcare sector to modulate drug delivery mechanisms more efficiently — could promote major growth in the next five years, according to a news release.
The researchers project that the market presents a $6 billion opportunity by 2026 as painless and non-invasive drug delivery methods become more and more sought after and cost-effectiveness and efficiency rise within the drug delivery and pharmaceutical space.
Kuick said the market has already experienced decades of “respectable” growth within a large market size, while it also presents promising business models that offer adaptability to patients.
Growing amounts of resources and technologically-driven innovations are only contributing to the rise of the market, researchers say, as they claim the transdermal patch space is a “constructive sector” for the entire U.S. pharmaceutical market.
The research concludes that, given the factors driving transdermal drug delivery, the overall market in the U.S. can be seen as a “dominant leader” over several decades to come.
